Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice.

ABSTRACT: Heart failure is becoming a global epidemic. It exerts a staggering toll on quality of life, and substantial medical and economic impact. In a pre-clinical model of cardiac hypertrophy and heart failure, we were able to overcome loss of heart function by administering the TRPV1 antagonist BCTC (4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide). The results presented here identify TRPV1 antagonists as new treatment options for cardiac hypertrophy and heart failure.

SUBMITTER: Horton JS 

PROVIDER: S-EPMC3589277 | biostudies-other | 2013 Jan

REPOSITORIES: biostudies-other